Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer

Frontiers in Endocrinology

Volumn 3, Issue APR, 2012, Pages

  Kypta, Robert ^a,b   Unda, Miguel ^c   Carracedo, Arkaitz ^a,d  

^a CIC BIOGUNE   (Spain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HOSPITAL DE BASURTO   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874408672     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00053     Document Type: Article

References (38)

1. Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., Rosivatz, E., Woscholski, R., Cognetti, F., Scher, H. I., and Pandolfi, P. P. (2010). A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681-693.
2. Attard, G., Reid, A. H., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., and De Bono, J. S. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507-516.
3. Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., Scardino, P. T., Rosen, N., and Sawyers, C. L. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586.
4. Carver, B. S., Tran, J., Chen, Z., Carracedo-Perez, A., Alimonti, A., Nardella, C., Gopalan, A., Scardino, P. T., Cordon-Cardo, C., Gerald, W., and Pandolfi, P. P. (2009a). ETS rearrangements and prostate cancer initiation. Nature 457, E1; discussion E2-E3.
5. Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., Cordon-Cardo, C., Gerald, W., and Pandolfi, P. P. (2009b). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624.
6. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., Cordon-Cardo, C., and Pandolfi, P. P. (2005). Crucial role of p53-dependent cellular senes-cence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
7. Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., Ellwood-Yen, K., Gerald, W. L., Sander, C., and Sawyers, C. L. (2011). MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 6, e17449. doi: 10.1371/journal.pone.0017449
8. Colleselli, D., Stenzl, A., and Schwentner, C. (2010). Re: florian jentzmik, carsten stephan, kurt miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identi-fication of aggressive tumours. Eur. Urol. 58, 12-18; Eur. Urol. 58, e51.
9. Davies, N. J., Batehup, L., and Thomas, R. (2011). The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br. J. Cancer 105(Suppl. 1), S52-S73.
10. De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B. Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., and Scher, H. I. (2011). Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005.
11. Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., and Sotiriou, C. (2008). Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165.
12. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355.
13. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., and Sawyers, C. L. (2003). Myc-driven murine pros-tate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238.
14. Friedlander, T. W., Roy, R., Tomlins, S. A., Ngo, V. T., Kobayashi, Y., Azameera, A., Rubin, M. A., Pienta, K. J., Chinnaiyan, A., Ittmann, M. M., Ryan, C. J., and Paris, P. L. (2012). Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 72, 616-625.
15. Hewavitharana, A. K. (2010). Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggres-sive tumours. Eur. Urol. 58, 12-18; Eur. Urol. 58, e39-e40; author reply e41-e32.
16. Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57, 524-531.
17. Jentzmik, F., Stephan, C., Lein, M., Miller, K., Kamlage, B., Bethan, B., Kristiansen, G., and Jung, K. (2011). Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and bio-chemical progression. J. Urol. 185, 706-711.
18. Jentzmik, F., Stephan, C., Miller, K., Schrader, M., Erbersdobler, A., Kristiansen, G., Lein, M., and Jung, K. (2010). Sarcosine in urine after digital rectal exami-nation fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58, 12-18; discussion 20-11.
19. Khandekar, M. J., Cohen, P., and Spiegelman, B. M. (2011). Molecular mechanisms of cancer develop-ment in obesity. Nat. Rev. Cancer 11, 886-895.
20. King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., Gerald, W. L., and Sawyers, C. L. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526.
21. Markert, E. K., Mizuno, H., Vazquez, A., and Levine, A. J. (2011). Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. U.S.A. 108, 21276-21281.
22. Massie, C. E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., Bon, H., Zecchini, V., Smith, D. M., Denicola, G. M., Mathews, N., Osborne, M., Hadfield, J., Macarthur, S., Adryan, B., Lyons, S. K., Brindle, K. M., Griffiths, J., Gleave, M. E., Rennie, P. S., Neal, D. E., and Mills, I. G. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30, 2719-2733.
23. Matros, E., Wang, Z. C., Lodeiro, G., Miron, A., Iglehart, J. D., and Richardson, A. L. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res. Treat. 91, 179-186.
24. Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., and Montgomery, R. B. (2011). Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913-5925.
25. Moul, J. W., and Dawson, N. (2012). Quality of life asso-ciated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest. 30, 1-12.
26. Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., and Wu, H. (2011). Cell autonomous role of PTEN in regulating castration-resistant pros-tate cancer growth. Cancer Cell 19, 792-804.
27. Perou, C. M., Sorlie, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
28. Putluri, N., Shojaie, A., Vasu, V. T., Nalluri, S., Vareed, S. K., Putluri, V., Vivekanandan-Giri, A., Byun, J., Pennathur, S., Sana, T. R., Fischer, S. M., Palapattu, G. S., Creighton, C. J., Michailidis, G., and Sreekumar, A. (2011). Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS ONE 6, e21417. doi: 10.1371/journal.pone.0021417
29. Qian, J., Jenkins, R. B., and Bostwick, D. G. (1997). Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluores-cence in situ hybridization. Mod. Pathol. 10, 1113-1119.
30. Salmena, L., Carracedo, A., and Pandolfi, P. P. (2008). Tenets of PTEN tumor suppression. Cell 133, 403-414.
31. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C., and Chinnaiyan, A. M. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
32. Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Van Dyke, T., Cordon-Cardo, C., and Pandolfi, P. P. (2003). Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59. doi: 10.1371/journal.pbio.0000059
33. Van 't Veer, L. J., Dai, H., Van De Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., Van Der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
34. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
35. Wang, Z. C., Lin, M., Wei, L. J., Li, C., Miron, A., Lodeiro, G., Harris, L., Ramaswamy, S., Tanenbaum, D. M., Meyerson, M., Iglehart, J. D., and Richardson, A. (2004). Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 64, 64-71.
36. Weinstein, B. (2008). Relevance of the concept of onco-gene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv. Exp. Med. Biol. 617, 3-13.
37. Weinstein, I. B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68, 3077-3080; discussion 3080.
38. Wolin, K. Y., Carson, K., and Colditz, G. A. (2010). Obesity and cancer. Oncologist 15, 556-565.